Cynata TherapeuticsCYYNF 14-Day RSI is 0.09 as of Jul. 03, 2026. The stock has 1 warning sign investors should review. Among 1,423 Biotechnology companies, Cynata Therapeutics ranks better than 99.44% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Cynata Therapeutics 14-Day RSI Related Terms
CYYNF vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Cynata Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cynata Therapeutics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cynata Therapeutics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Cynata Therapeutics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cynata Therapeutics (CYYNF) has a 14-Day RSI of 0.09 as of Jul. 03, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Cynata Therapeutics and its competitors. According to the industry distribution chart, Cynata Therapeutics ranks #8 out of 1423 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is Cynata Therapeutics' 14-Day RSI too high?
Cynata Therapeutics' current 14-Day RSI is 0.09. The Biotechnology industry median 14-Day RSI is 49.99. Cynata Therapeutics' value of 0.09 is 99.8% below this industry median. Based on the distribution chart, Cynata Therapeutics ranks #8 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Cynata Therapeutics' 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cynata Therapeutics ranks #8 out of 1423 companies for 14-Day RSI. This places Cynata Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 49.99. Cynata Therapeutics' value of 0.09 is 99.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.99, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cynata Therapeutics's current 14-Day RSI of 0.09 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Cynata Therapeutics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cynata Therapeutics's current 14-Day RSI is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cynata Therapeutics stock overvalued right now?
Cynata Therapeutics (CYYNF) has a current 14-Day RSI of 0.09. The current 14-Day RSI is 0.09 and 99.8% below the Biotechnology industry median of 49.99. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Cynata Therapeutics (CYYNF), the current 14-Day RSI is 0.09 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CYYNF has been successfully added to your